Racura Oncology (ASX:RAC) Total Equity: A$23.57 Mil (As of Dec. 2025)


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.21
View Full Analysis

What is Racura Oncology Total Equity?

Racura Oncology ASX:RAC -5.96% 31 Total Equity is A$23.57 Mil as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 31/100.

Racura Oncology's total equity for the quarter that ended in Dec. 2025 was A$23.57 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Racura Oncology Total Equity Historical Data

* Premium members only.

The historical data trend for Racura Oncology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Total Equity Chart

Racura Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.72 36.11 25.49 18.31 16.01

Racura Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.43 18.31 20.72 16.01 23.57
ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Racura Oncology's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=17.49-1.479
=16.01

Racura Oncology's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=24.767-1.197
=23.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$23.57 Mil mean?
Racura Oncology (ASX:RAC) has a Total Equity of A$23.57 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Racura Oncology and its competitors.
Is Racura Oncology's Total Equity too high?
Racura Oncology's current Total Equity is A$23.57 Mil. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Total Equity compare to VRTX and REGN?
Racura Oncology's Total Equity of A$23.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Racura Oncology and its competitors. Racura Oncology's current Total Equity is A$23.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Total Equity of A$23.57 Mil. The current Total Equity is A$23.57 Mil. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Total Equity is A$23.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21
Price